BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 27189323)

  • 21. [Combination of S-1 and paclitaxel for advanced/recurrent gastric cancer patients with peritoneal metastasis, feasibility study (OGSG0401)].
    Kimura Y; Machida H; Fujitani K; Yamamoto M; Tominaga K; Yano H; Shimokawa T; Takiuchi H; Tsujinaka T; Furukawa H
    Gan To Kagaku Ryoho; 2010 Jan; 37(1):151-5. PubMed ID: 20087052
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multi-center phase II study for combination therapy with paclitaxel/doxifluridine to treat advanced/recurrent gastric cancer showing resistance to S-1 (OGSG 0302).
    Takiuchi H; Goto M; Imamura H; Furukawa H; Imano M; Imamoto H; Kimura Y; Ishida H; Fujitani K; Narahara H; Shimokawa T
    Jpn J Clin Oncol; 2008 Mar; 38(3):176-81. PubMed ID: 18281707
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Switch maintenance therapy with S-1 after induction therapy with carboplatin and nanoparticle albumin-bound paclitaxel in advanced lung squamous cell carcinoma.
    Akiyama N; Karayama M; Inui N; Yasui H; Hozumi H; Suzuki Y; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Inami N; Matsuura S; Kaida Y; Uto T; Matsui T; Asada K; Matsuda H; Fujii M; Toyoshima M; Suda T
    Invest New Drugs; 2019 Jun; 37(3):531-537. PubMed ID: 30790149
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I study of biweekly intravenous paclitaxel plus intraperitoneal cisplatin and paclitaxel for gastric cancer with peritoneal metastasis.
    Ishigami H; Kitayama J; Kaisaki S; Yamaguchi H; Yamashita H; Emoto S; Nagawa H
    Oncology; 2010; 79(3-4):269-72. PubMed ID: 21372602
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase 1 study of Gemcitabine/Nab-paclitaxel/S-1 in patients with unresectable pancreatic cancer (GeNeS1S trial).
    Sai S; Toyoda M; Tobimatsu K; Satake H; Yasui H; Kimbara S; Koyama T; Fujishima Y; Imamura Y; Funakoshi Y; Kiyota N; Toyama H; Kodama Y; Minami H
    Cancer Chemother Pharmacol; 2021 Jan; 87(1):65-71. PubMed ID: 33098471
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase I study of combination therapy of the oral fluorinated pyrimidine compound S-1 with low-dose cisplatin twice-a-week administration (JFMC27-9902 Step2) in patients with advanced gastric cancer using a continual reassessment method.
    Morita S; Nakata B; Tsuji A; Mitachi Y; Shirasaka T; Saji S; Ohashi Y; Sakamoto J; Hirakawa K
    Jpn J Clin Oncol; 2007 Dec; 37(12):924-9. PubMed ID: 18211983
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I Study of Triweekly Nab-Paclitaxel Combined with S-1 in Patients with HER2-negative Metastatic Breast Cancer.
    Sakaguchi K; Nakatsukasa K; Taguchi T
    Anticancer Res; 2016 Dec; 36(12):6515-6519. PubMed ID: 27919976
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of S-1 and oxaliplatin combination therapy in elderly patients with advanced gastric cancer.
    Bando H; Yamada Y; Tanabe S; Nishikawa K; Gotoh M; Sugimoto N; Nishina T; Amagai K; Chin K; Niwa Y; Tsuji A; Imamura H; Tsuda M; Yasui H; Fujii H; Yamaguchi K; Yasui H; Hironaka S; Shimada K; Miwa H; Hamada C; Hyodo I
    Gastric Cancer; 2016 Jul; 19(3):919-26. PubMed ID: 26474989
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized phase II study comparing paclitaxel with S-1 vs. S-1 as first-line treatment in patients with advanced gastric cancer.
    Wang X; Wang ML; Zhou LY; Lu XY; Yang JF; Yu HG
    Clin Transl Oncol; 2013 Oct; 15(10):836-42. PubMed ID: 23381898
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I/II study of a combination of S-1 and weekly paclitaxel in patients with advanced or recurrent gastric cancer.
    Kawabata R; Fujiwara Y; Doki Y; Fujita J; Tsukahara Y; Yamasaki M; Miyata H; Takiguchi S; Monden M
    Oncology; 2007; 72(3-4):219-25. PubMed ID: 18176087
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical evaluation of cetuximab combined with an S-1 and oxaliplatin regimen for Chinese patients with advanced gastric cancer.
    Zhang ZD; Kong Y; Yang W; Zhang B; Zhang YL; Ma EM; Liu HX; Chen XB; Hua YW
    World J Surg Oncol; 2014 Apr; 12():115. PubMed ID: 24758484
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase II study of biweekly S-1 and paclitaxel (SPA) as first-line chemotherapy in patients with metastatic or advanced gastric cancer.
    Jiang H; Qian J; Zhao P; Zhang X; Zheng Y; Mao C; Zheng Y; Chen L; Wang Y; Mou H; Fang W; Teng L; Xu N
    Cancer Chemother Pharmacol; 2015 Jul; 76(1):197-203. PubMed ID: 26013324
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer.
    Hironaka S; Zenda S; Boku N; Fukutomi A; Yoshino T; Onozawa Y
    Gastric Cancer; 2006; 9(1):14-8. PubMed ID: 16557431
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase I study of bi-weekly combination therapy with S-1 and docetaxel for advanced or recurrent gastric cancer.
    Rino Y; Takanashi Y; Yukawa N; Saeki H; Wada H; Kanari M; Yamada R; Satoh T; Yamamoto N; Imada T
    Anticancer Res; 2006; 26(2B):1455-62. PubMed ID: 16619558
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intraperitoneal infusion of paclitaxel with S-1 for peritoneal metastasis of advanced gastric cancer: phase I study.
    Kurita N; Shimada M; Iwata T; Nishioka M; Morimoto S; Yoshikawa K; Higashijima J; Miyatani T; Nakao T
    J Med Invest; 2011 Feb; 58(1-2):134-9. PubMed ID: 21372498
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase 2 trial of intravenous and intraperitoneal paclitaxel combined with S-1 for treatment of gastric cancer with macroscopic peritoneal metastasis.
    Yamaguchi H; Kitayama J; Ishigami H; Emoto S; Yamashita H; Watanabe T
    Cancer; 2013 Sep; 119(18):3354-8. PubMed ID: 23798046
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase 1 Dose-Escalation Study of Triweekly Nab-Paclitaxel Combined With S-1 for HER2-Negative Metastatic Breast Cancer.
    Morimoto M; Toba H; Aoyama M; Nakagawa M; Takechi H; Yoshida T; Tangoku A
    Clin Breast Cancer; 2020 Dec; 20(6):448-453. PubMed ID: 32800494
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A multicenter phase II study of biweekly paclitaxel and S-1 combination chemotherapy for unresectable or recurrent gastric cancer.
    Nakajo A; Hokita S; Ishigami S; Miyazono F; Etoh T; Hamanoue M; Maenohara S; Iwashita T; Komatsu H; Satoh K; Aridome K; Morita S; Natsugoe S; Takiuchi H; Nakano S; Maehara Y; Sakamoto J; Aikou T;
    Cancer Chemother Pharmacol; 2008 Nov; 62(6):1103-9. PubMed ID: 18317763
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intraperitoneal Administration of Paclitaxel Followed by Paclitaxel, Cisplatin, and S-1 Chemotherapy for Cytology-positive Gastric Cancer: A Feasibility Study.
    Shinkai M; Imano M; Chiba Y; Hiraki Y; Kato H; Iwama M; Shiraisi O; Yasuda A; Tsubaki M; Nishida S; Kimura Y; Yasuda T
    Anticancer Res; 2018 Oct; 38(10):5969-5974. PubMed ID: 30275227
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I/II Study of S-1 Plus Cisplatin Alternating With S-1 Plus Docetaxel in Patients With Advanced Gastric Cancer.
    Hosokawa A; Ando T; Ogawa K; Ueda A; Yoshita H; Mihara H; Fujinami H; Kajiura S; Yabushita K; Horikawa N; Kobayashi Y; Yoshioka A; Origasa H; Sugiyama T
    Am J Clin Oncol; 2018 Oct; 41(10):977-981. PubMed ID: 28930775
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.